Skip to content
Linkedin
RLS logo_header
  • Drug Approvals
  • Regulatory News
  • Trial Results
  • Trial Status
  • Business News
  • Conference Coverage
  • About Us
  • Drug Approvals
  • Regulatory News
  • Trial Results
  • Trial Status
  • Business News
  • Conference Coverage
  • About Us
  • Choose Speciality

    Post content

    • Brain Cancer
    • Breast Cancer
      • HER2+ HRneg Breast Cancer
      • HR+ HER2neg Breast Cancer
      • TNBC
    • GI Cancers
      • Cholangiocarcinoma
      • Colorectal Cancer
      • Esophageal Cancer
      • Gastric Cancer
      • GEJ
      • GIST
      • HCC
      • Pancreatic Cancer
    • GU Cancers
      • Bladder Cancer
      • Prostate Cancer
      • Renal Cell Carcinoma
    • Gynecological Cancers
      • Cervical Cancer
      • Endometrial Cancer
      • Ovarian Cancer
    • Head & Neck Cancer
      • Nasopharyngeal Carcinoma
      • Oropharyngeal Cancer
    • Hematological Malignancies
      • CAR-Ts
    • Leukemias
      • ALL
      • AML
      • Chronic Myeloid Leukemia
      • CLL/SLL
      • CMML
    • Lung Cancer
      • Biomarker-Driven Lung Cancer
      • EGFR+ Lung Cancer
      • Non-Small Cell Lung Cancer
      • Small Cell Lung Cancer
    • Lymphomas
      • DLBCL
      • Follicular Lymphoma
      • Hodgkin’s Lymphoma
      • Mantle Cell Lymphoma
      • Non-Hodgkin’s Lymphoma
      • T-Cell Lymphoma
    • MPNs
    • Multiple Myeloma
    • Myelodysplastic Syndromes
    • Neuroendocrine Tumors
    • Sarcoma
    • Skin Cancer
    • Solid Tumors
    • Thyroid Cancer
    • Uveal Melanoma
  • Drug Approvals
  • Regulatory News
  • Trial Results
  • Trial Status
  • Business News
  • Conference Coverage
  • About Us
  • Drug Approvals
  • Regulatory News
  • Trial Results
  • Trial Status
  • Business News
  • Conference Coverage
  • About Us
  • Choose Speciality

    Post content

    • Brain Cancer
    • Breast Cancer
      • HER2+ HRneg Breast Cancer
      • HR+ HER2neg Breast Cancer
      • TNBC
    • GI Cancers
      • Cholangiocarcinoma
      • Colorectal Cancer
      • Esophageal Cancer
      • Gastric Cancer
      • GEJ
      • GIST
      • HCC
      • Pancreatic Cancer
    • GU Cancers
      • Bladder Cancer
      • Prostate Cancer
      • Renal Cell Carcinoma
    • Gynecological Cancers
      • Cervical Cancer
      • Endometrial Cancer
      • Ovarian Cancer
    • Head & Neck Cancer
      • Nasopharyngeal Carcinoma
      • Oropharyngeal Cancer
    • Hematological Malignancies
      • CAR-Ts
    • Leukemias
      • ALL
      • AML
      • Chronic Myeloid Leukemia
      • CLL/SLL
      • CMML
    • Lung Cancer
      • Biomarker-Driven Lung Cancer
      • EGFR+ Lung Cancer
      • Non-Small Cell Lung Cancer
      • Small Cell Lung Cancer
    • Lymphomas
      • DLBCL
      • Follicular Lymphoma
      • Hodgkin’s Lymphoma
      • Mantle Cell Lymphoma
      • Non-Hodgkin’s Lymphoma
      • T-Cell Lymphoma
    • MPNs
    • Multiple Myeloma
    • Myelodysplastic Syndromes
    • Neuroendocrine Tumors
    • Sarcoma
    • Skin Cancer
    • Solid Tumors
    • Thyroid Cancer
    • Uveal Melanoma
Linkedin

FAILED TRIAL: Ph 2 KeyVibe-002 Trial of MK-7684A (Vibostolimab + Pembrolizumab) in Previously Treated NSCLC patients did not meet primary PFS endpoint

March 31, 2023

Pivotal Ph 3 INDIGO Trial of vorasidenib in IDH-Mutant Low-Grade Glioma Meets Primary Endpoint of PFS and Key Secondary Endpoint of Time to Next Intervention (TTNI)

March 31, 2023

Dose Escalation Portion of Phase 1 Solid Tumors Trial of TRE-515 Produces Favorable Results in Heavily Pretreated Solid Tumor Patients

March 31, 2023

Ph 3 Study Shows XTANDI® (enzalutamide) plus Leuprolide Significantly Improves Metastasis-Free Survival in Men with Non-Metastatic Prostate Cancer

March 31, 2023

A First Complete Bone Marrow Response in a R/R AML Patient From The Very Low Dose Arm of Its AB8939 Ph 1/2 Clinical Trial (AB18001) reported

March 31, 2023

Ph 3 China ARCHES Study of XTANDI® Meets Primary Endpoint

March 31, 2023

KEYTRUDA + Chemo Significantly Improved PFS vs chemo Alone as 1L Therapy for Advanced or Recurrent Endometrial Carcinoma, Regardless of MMR Status

March 31, 2023

Kisqali® Ph 3 NATALEE Trial Meets Primary Endpoint At Interim Analysis Demonstrating Clinically Meaningful Benefit In Patients With Early Breast Cancer

March 31, 2023

Zolbetuximab Improves Survival in Gastric Cancer

March 31, 2023

Patritumab Deruxtecan Continues to Show Encouraging Clinical Activity in Distinct Patient Populations with Metastatic Lung and Breast Cancer in Updated Results of Two Early Trials

March 31, 2023

Botensilimab + Balstilimab combo Shows 33% Durable Responses in Ovarian Cancer

March 31, 2023

Yescarta® Demonstrates Statistically Significant OS Improvement for Initial Treatment of R/R Large B-cell Lymphoma

March 31, 2023

Ph 3 KEYNOTE-671 Trial Met Primary Endpoint of EFS in Patients With Resectable Stage II, IIIA or IIIB NSCLC

March 15, 2023

Tagrisso demonstrated strong OS benefit in the ADAURA Ph 3 trial for adjuvant treatment of patients with early-stage EGFR-mutated lung cancer

March 15, 2023

Imfinzi significantly improved EFS in AEGEAN Ph 3 trial for patients with resectable NSCLC

March 15, 2023

RXC004 Topline Data From Ph 2 Monotherapy Module leads to program discontinuation

March 15, 2023

KEYTRUDA + Chemo Significantly Improved OS vs chemo Alone as First-Line Treatment for Advanced Malignant Pleural Mesothelioma

March 15, 2023

ACE-Breast-02 Pivotal Ph 3 Study of ARX788 for the Treatment of HER2 Positive Metastatic Breast Cancer Achieves Positive Results

March 15, 2023

FAILED TRIAL: Ph 3 CONTACT-03 study of cabozantinib + atezolizumab versus cabozantinib alone in RCC patients did not meet primary endpoint of PFS

March 15, 2023

Enhertu Showed Clinically Meaningful and Durable Responses Across Multiple HER2-Expressing Tumour Types in DESTINY-PanTumor02 Ph 2 Trial

March 15, 2023

Updated survival data from Ph 2 trial of Bria-IMT™ + retifanlimab combo in advanced metastatic breast cancer patients announced

February 28, 2023

Positive Full Data Results From the Pivotal Ph 3 SIERRA Trial in Patients with Active, R/R AML announced

February 28, 2023

ESMO 2023: Ad hoc interim OS study results of ZEJULA® (niraparib) from the NORA Ph 3 study and a post hoc analysis from the Ph 3 PRIME trial of niraparib maintenance therapy to be presented

February 28, 2023

Positive Initial Results From The MVP-S Ph 2B VITALIZE Trial Presented

February 22, 2023

Positive Final OS Results of Ph 3 JUPITER-02 Trial of Toripalimab as Treatment for Recurrent or mNPC announced

February 22, 2023
Page1 … Page22 Page23 Page24 Page25 Page26 … Page30

Onco-This-Week

  • Business News
  • Drug Approvals
  • Regulatory News
  • Trial Results
  • Trial Status
  • Conference Coverage

About Us

Sign up for OTW

Linkedin

Disclaimer: The OTW team takes care to share authentic information. In case of any discrepancies please write to newsletter@onco-this-week.com. Our website is an aggregator for open-source oncology news. The information on our website is provided without any representations or warranties. OTW is part of RLS Consultants, a global consulting and training firm focusing exclusively on the healthcare and life sciences industries. RLS is a leading provider of opportunity assessment services, utilizing its comprehensive expertise in strategic market research, forecasting, and modeling, as well as pricing and market access to facilitate commercial assessments. RLS does not have any influence on any news reported on OTW. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of RLS. The content on our website is intended strictly for news and information purposes only and should not be treated as a substitute for medical advice, diagnosis, or treatment. News shared on OTW should not be utilized in real-world analytic products as they are based only on limited and dated open-source information.